Hints and tips:
...Stephen Hoge, Moderna’s president, said: “We will not sell it at cost.”...
...“If [mRNA] does work, you could cede the whole market to Moderna or Pfizer,” said Geoffrey Porges, an analyst at healthcare-focused investment bank SVB Leerink....
...The market is unlikely to be winner-takes-all, according to Geoffrey Porges, an analyst at SVB Leerink. While supply is constrained during the pandemic, every approved vaccine will be needed....
...However, Geoffrey Porges, a biotech analyst at SVB Leerink, said the current level of scrutiny directed at Gilead is “unprecedented”....
...Geoffrey Porges, senior biotechnology analyst at SVB Leerink, said the 50 per cent probability was probably conservative....
...“Dear Mr and Mrs Porges,” it begins. “Enclosed you find the check for the amount of $286.00....
International Edition